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Fabry disease (FD) is a lysosomal storage disorder where deficient or completely 
absent activity of the enzyme α-galactosidas A leads to accumulation of globotriao-
sylceramide (Gb3) and other glycosphingolipids in lysosomes. The condition is rare, 
approximately 1:50,000, although underdiagnosis seems frequent. The condition 
can affect multiple organ systems, including the skin, nervous system, kidneys, and 
heart. Early manifestations include skin lesions (angiokeratoma), neuropathic pain, 
and gastrointestinal symptoms. Later on, FD can result in cardiomyopathy, kidney 
failure, and stroke. Both lifespan and health-related quality of life are affected nega-
tively by FD. Patients are divided into a classical or a non-classical phenotype based 
on presentation, where the diagnosis of classical FD requires that a set of specific 
criteria are met. Patients with non-classical FD often have a less severe disease 
course, sometimes limited to one organ. The hereditary pattern is X-linked. Thus, 
men are in general more severely affected than women, although there is an overlap 
in symptomatic burden. Two types of specific treatment options are available: 
enzyme replacement therapy and pharmacological chaperone therapy. In addition 
to this, management of each organ manifestation with usual treatment is indicated.
Keywords: Fabry disease, hypertrophic cardiomyopathy, left ventricular 
hypertrophy, lysosomal storage disorder
1. Introduction
Anderson-Fabry disease, generally referred to as Fabry disease (FD), is a 
lysosomal storage disorder where the activity of lysosomal enzyme α-galactosidas 
A is deficient or completely absent. This leads to accumulation of globotriaosylce-
ramide (Gb3) and related glycosphingolipids inside the lysosomes [1], organelles 
which, among other things, are responsible for degradation of cellular waste [2]. 
FD is a rare condition, and the reported incidence varies greatly between sources, 
with reported incidences in the ranges of 1 in 40,000 [3], 1 in 117,000 [4], and 1 
in 476,000 [5]. However, when screening newborn males a prevalence of around 
1 in 3,100 was found in Italy [6] and 1 in 1,250 in Taiwan [7], suggesting the true 
prevalence is higher than previously thought [1].
2. Historical overview
In 1898, the German physician Johannes Fabry and the British surgeon William 
Anderson independently of each other reported seeing patients with angiokera-
toma, a classical skin lesion associated with the disease [8–10]. Back then, physi-
cians lacked knowledge about the underlying causes for the dermatoses they were 
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describing, and the meaning of additional symptoms were mostly unknown [11]. 
Hence, FD was initially considered a purely dermatological disorder. Anderson 
did, however, describe proteinuria. No one else in the patient’s family was affected. 
Fabry’s patient had a paternal grandfather who passed away from “kidney trouble” 
at an age of 49 years, and the patient himself died of lung disease at 44 years of age. 
The average life expectancy in the general population in the year 1900 was about 
40 years [11]. In 1963 the mainly accumulated substance, Gb3, was identified [12]. 
A few years later, deficient α-galactosidas activity was described, followed by the 
discovery of the gene coding for α-galactosidas A. To date, almost a 1,000 muta-
tions have been identified in this gene, although many of the mutations still have an 
unknown significance and it is unclear whether they cause FD [8].
3. Disease manifestations
Symptoms generally appear between ages 3 and 10 in males, and a few years later 
in females [1]. Pain is among the first symptoms to manifest, and it can be either as 
episodic crises or as chronic pain. Most often, it presents as episodic sensations that 
radiate proximally from the extremities, which can be burning or shooting in char-
acter. The pain crises can consist of excruciating pain spreading all across the body. 
Physical exercise and thermal stimuli are triggers of the pain [13]. In addition to 
this, patients with FD can suffer from heat intolerance due to an- or hypohidrosis. 
In some patients, the pain decreases as they reach adulthood [1]. Other symptoms 
that may develop early are gastrointestinal problems (abdominal pain, diarrhea, 
vomiting), angiokeratoma (small spots on the skin, dark-red and raised), tinnitus 
and corneal changes (cornea verticillata, rarely affecting vision, Figure 1) [1].
For a definite diagnosis of FD, presence of an α-galactosidas A gene mutation 
needs to be present. Furthermore, in males an α-galactosidas A deficiency of ≤5% 
of mean reference value in leukocytes is an additional criterion, whilst in females 
α-galactosidas A in leukocytes may be normal or deficient. Additionally, one of the 
Figure 1. 
Cornea verticillata, seen as sub-epithelial brown lines. From Germain [1]. Courtesy: Dr. Juan-Manuel 




following must be present: at least one characteristic sign of FD (neuropathic pain, 
cornea verticillata, or clustered angiokeratoma), increased plasma Gb3 (in the range 
of males with definite FD diagnosis), or a family member with definite FD with the 
same α-galactosidas A gene mutation [14].
FD is divided into a classical or a non-classical phenotype, where the diagnosis 
of classical phenotype in males is based on presence of an α-galactosidas A gene 
mutation, very low or completely absent enzyme activity, and one of the following 
signs: angiokeratoma, cornea verticillata, or very high Gb3-levels [15]. Hemizygous 
males are in general the ones most severely affected, although heterozygous females 
often have serious manifestations, which affect both quality of life and lifespan 
[16]. The varying severity of FD in females, where some are asymptomatic and 
others have a disease course comparable to that of males, is believed to be a result of 
skewed X-chromosome inactivation [17]. Females are considered to have classical 
FD when they present with angiokeratoma, cornea verticillata, or a very high Gb3-
level [15]. Although the disease course is variable (more so in non-classical than in 
classical FD), patients with non-classical FD are less severely affected in general, 
sometimes with disease manifestation limited to one organ [18].
The heart, kidneys and brain may become affected as the disease progresses, 
and cardiovascular, renal and cerebrovascular disease represent the most common 
among the known and reported causes for mortality in patients with FD [16].
3.1 Cardiac involvement
Heart involvement is the main reason for impaired quality of life and death 
in patients with FD [19]. Between 40 and 60% report symptoms including left 
ventricular hypertrophy (LVH), angina, arrhythmia and dyspnea [1]. In most 
studies the prevalence of FD in adult patients with left ventricular hypertrophy is 
estimated at 0.5–1% [20]. For a suggestion on how to further investigate LVH that 
might be associated with FD, see Figure 2. Many patients have a cardiac variant of 
FD, meaning the disease manifests later in life, primarily as LVH or hypertrophic 
cardiomyopathy (HCM). This variant generally progresses slower because of 
Figure 2. 
Suggestion for further investigation of LVH when FD is suspected. Agal, α-galactosidas A; EMB, 
endomyocardial biopsy; GLA, α-galactosidas A gene; GLS, global longitudinal strain; RVH, right ventricular 
hypertrophy; VUS, variant of unknown significance. Image by Linhart A et al. [20] licensed under CC 
BY-NC 4.0.
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residual α-galactosidas A-activity [20]. LVH manifests on average at age 32 in males, 
and at age 40 in women [21]. It is usually not accompanied by significantly impaired 
systolic function or restrictive diastolic dysfunction [22]. FD is considered a sub-
group of HCM by the European Society of Cardiology (ESC), while the American 
Heart Association uses the term phenocopy to describe FD and other mimics of 
HCM [23, 24]. The prevalence of FD among patients with HCM above age 35–40 
has been estimated to 0.5% [25].
In addition to LVH, cardiac involvement may lead to conduction defects and 
arrhythmia [8]. Since symptomatic bradycardia, AV block, chronotropic incompe-
tence, supraventricular and ventricular arrhythmias are common, regular 24 h ECG 
monitoring is recommended [20]. The ESC recommend that patients with HCM 
who present with AV block or chronotropic incompetence should be suspected 
of having FD [23]. The arrhythmias in FD are a cause of significant morbidity. 
Atrial fibrillation is four times more common in patients with FD than in the 
general population, and twelve times more common in patients above the age of 
50 [26]. Death from ventricular arrhythmia has been observed in a number of FD 
patients [26, 27]. Patients with FD can experience angina despite their coronary 
arteries being angiographically normal, which can be explained by microvascular 
dysfunction [28]. Valve disease occurs as a result of infiltrative changes in valvular 
fibroblasts, most clinically significant changes appear in the left heart valves. Valves 
become thickened which can lead to mild to moderate regurgitation, but disease 
requiring surgery is rare [29].
ECG changes associated with FD include shorter PQ interval, P-wave duration 
and QRS width, and increased QT and QTc duration [30]. As FD cardiomyopathy 
develops, voltage signs of LVH and inversed T-waves in precordial leads are usually 
seen [20].
Terminal stage cardiac FD leads to severe left ventricle dysfunction, associated 
with conduction disturbances and ventricular arrhythmia [27].
3.2 Renal involvement
The kidneys can be affected due to Gb3 accumulating in renal cells (glomerular 
endothelial, mesangial, interstitial, podocytes), and the severity increases with 
age [1]. The first signs are usually microalbuminuria and proteinuria, presenting 
as early as the second decade of life and worsening with age [1]. In time, the glo-
merular filtration rate starts to decline, which might lead to end-stage renal failure 
[8]. Renal involvement is common; signs and symptoms of renal disease have been 
reported in half of patients in the Fabry Outcome Survey (a European database for 
all FD patients eligible for, or receiving, enzyme replacement therapy with agalsi-
dase alfa). The most frequent sign was proteinuria, seen in 33% of females and 44% 
of males. End-stage renal failure affected 17% of males and 1% of females. Among 
the male patients 10% received a renal transplant and 7% were on dialysis [3].
3.3 Cerebrovascular involvement
Ischemic stroke and transient ischemic attacks are the most common cere-
brovascular complications in FD, and occur at a younger age than in the general 
population [31]. Stroke can affect patients who have no other key signs of FD; data 
from the Fabry Registry showed that 46% suffered their first stroke prior to being 
diagnosed with FD [32]. The median age of first stroke was 39 in males and 46 in 
females. Approximately 87% of strokes were ischemic similar to the numbers in 
the general population. Among the strokes where vessel size was reported, most 




in males, which by far exceeds the prevalence in the general population [1]. In men 
between ages 35 and 45, the risk of stroke is 12.2 times higher in patients with FD 
than in healthy subjects [31].
The pathological mechanisms for stroke in FD is not clear, but abnormalities in 
cerebral blood flow as well as in the walls of intracranial vessels have been seen [32]. 
A possible contributing factor is that formation of thrombi may be enhanced due to 
increased adhesion of neutrophils and monocytes to the endothelial wall [1, 33].
4. Pathophysiology
That Gb3 is accumulated in lysosomes is well known, but the specifics regarding 
what causes cellular dysfunction is not [8]. Accumulation of substrate does lead to 
enlargement of the affected cells, in turn resulting in enlargement of entire organs. 
This is, however, not the only explanation [34]. One report presents a case where 
cardiac hypertrophy resulted in a heart weighing 1100 g, and Gb3 only accounted 
for 3.5 g [35, 36]. Mitochondrial metabolism is affected by the substrate accumula-
tion in FD, which is part of the explanation for the organ damage that occurs [37]. 
There may be dysfunction of the endoplasmic reticulum as well. Fibrosis, inflam-
mation and oxidative stress appear to play important parts in pathogenesis [8].
5. Treatment
In 2001 enzyme replacement therapy (ERT) was introduced; human recombi-
nant α-galactosidas A administered through bi-weekly intravenous infusions. Two 
recombinant enzyme preparations exist: agalsidase alfa and agalsidase beta. ERT 
has been shown to reduce pain, improve cardiac function [38], and stabilize kidney 
function [39]. Treatment is recommended for classically affected males and females 
and non-classically affected males who show early clinical signs of heart, kidney, 
or brain involvement. In classically affected males aged 16 or older without signs 
or symptoms of organ involvement and in non-classically affected females with 
early clinical signs, treatment should be considered [15]. ERT should be prescribed 
as early in the disease course as possible, since the benefit in advanced FD seems 
doubtful [40, 41]. Although the risk of developing a first or second complication 
is reduced by increased treatment duration, ERT does not seem to prevent disease 
progression [40].
Since 2016 another treatment option has become available: pharmacological 
chaperone therapy (PCT). The drug is taken orally, and can restore enzyme activity 
by promoting correct folding in patients with mutations responsive to the therapy 
(approximately 35–50% of patients) [8, 42]. Individual eligibility for treatment is 
tested through an in vitro enzyme activity assay [43]. During long-term therapy it has 
maintained renal function, and reduced cardiac mass more effectively than ERT [42].
Both ERT and PCT should always be combined with therapies to manage the 
different organ manifestations clinically [8].
Regarding implantable cardioverter-defibrillator therapy, the ESC state that 
their risk prediction model HCM Risk-SCD, used for calculating the risk of sudden 
cardiac death (SCD) in HCM patients, should not be used in patients with FD [23]. 
There are currently no guidelines for implantation of cardiac devices in FD, and 
data on risk predictors are scarce. One study showed a higher delivery of device 
therapy in FD than in HCM. The rates of asymptomatic non sustained ventricular 
tachycardia were similar, but FD patients experienced a higher rate of ventricular 
arrhythmia that required anti-tachycardia pacing or defibrillation [44].
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6. Health-related quality of life
Patients with FD have a lower quality of life than the population in general; 
a systematic review found that they score lower in all domains in the SF-36 and 
EQ-5D questionnaires (the domains include aspects such as a physical and mental 
component summary score) [45]. However, no studies had examined the difference 
between classically and non-classically affected individuals. The effect of ERT on 
quality of life was not conclusive. A qualitative study using in-depth interviews with 
ten Norwegian women, heterozygous for FD, found that receiving the diagnosis 
can bring about feelings of relief as well as distress [46]. For symptomatic women 
the diagnosis can be an explanation of problems they have dealt with for years; 
many have been burdened by feeling like hypochondriacs because of health issues 
without an apparent cause. On the other hand, some women saw the diagnosis itself 
as stigmatizing. Almost every participant had negative feelings about passing the 
condition on to their children. Another qualitative study of 30 patients from the 
Netherlands, both male and female, found that many patients had experiences of 
being misdiagnosed and feeling misunderstood due to delayed correct diagnosis 
[47]. Others mentioned that presymptomatic diagnosis had drawbacks such as 
medicalization and labeling.
7. Prognosis
Before ERT, male patients died at a mean age of 50 [48], and a study of females 
showed a median cumulative survival of 70 years [49]. The long-term prognosis of 
FD in a modern setting needs to be further elucidated.
8. Future perspectives
There are current studies of gene therapy for FD, as well as substrate reduction 
therapy, second generation enzyme replacement therapies, and novel PCTs [8, 43]. 
The second generation enzyme replacement therapies currently in development are 
plant derived as opposed to agalsidase alfa (produced in human fibroblasts) and 
agalsidase beta (produced in hamster ovary cells), which could result in a differ-
ent bio distribution. Substrate reduction therapy is an oral treatment, which aims 
to limit the formation of metabolites that FD patients cannot degrade. There are 
currently ongoing Phase I and II clinical trials in which haematopoetic stem cells are 
recruited from the patient and transduced with the lentivirus vector containing the 
human α-galactosidas A gene, then re-administered to the patient (NCT02800070 
and NCT03454893) [43].
9. Conclusions
FD is a rare disease, generally underdiagnosed, with profound effects on mor-
bidity and mortality. Symptoms, such as debilitating pain, can present themselves 
early in childhood and in time the disease may lead to severe cardiac, renal, and 
cerebrovascular complications. The available treatment with ERT has a doubtful 
effect in advanced FD, making it imperative that the diagnosis is made in time. The 
Fabry Registry has been used in several studies of FD patients, and registry data is 
a valuable resource when it comes to evaluating treatment options. In the future, 
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registry can provide regarding clinical and investigative findings. The suffering 
associated with living with unexplained symptoms for years is yet another reason 
why increased awareness of FD in the medical community is of great importance.
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